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Thank you for submitting your manuscript for consideration by the EMBO Journal. We have now received three referee reports on your manuscript, which are included below for your information.
As you can see from the comments, all three referees express interest in the presented role of RhoB GTPase in plasma membrane blebbing induction. However, they also raise substantive concerns with the experimental setup and data conclusiveness and interpretation that would need to be addressed before they can support publication here. Based on the overall interest expressed in the reports, I would like to invite you to submit a revised version of your manuscript in which you address the comments of all three referees. I would ask you to focus in particular on the following points:
-Clarify the potential redundancy between RhoA and RhoB in membrane blebbing regulation (reviewer #1, point 4) -Provide appropriate data quantification as requested by reviewer #2, point 1.
-Provide convincing evidence based on the analysis of endogenous RhoB for the importance of plasma membrane localisation for its role in blebbing (reviewer #2, point 2; reviewer #3, points 1 and 7). -Provide further evidence for the importance of endosomal recycling and KIF13A for RhoB function (reviewer #1, point 3; reviewer #2, points 3 and 4; reviewer #3, points 3, 6, 7 and 8) I should add that it is The EMBO Journal policy to allow only a single major round of revision and that a conclusive and convincing resolution of these issues will be required to consider publication here. Since extensive additional work with an uncertain outcome would be needed to fulfill all the referee requests, I would understand if you were to choose not to undergo an extensive revision here and rather pursue a submission at an alternative venue, in which case please inform us about your decision at your earliest convenience.
On MS page 11, is "TagRFP-tagged RhoB" correct?
In the figures, it isn't always clear which conditions are being compared to which when the statistical significance is indicated by asterisks. Could this be indicated in the figure, or at least described in the figure legends.
Referee #2:
The authors have identified a specific role of RhoB (compared to RhoA and RhoC) in the formation of blebs during tumor cell migration/invasion. After the analysis of the different effects observed after silencing either RhoA, B, or C protein, they conclude that the role played by RhoB in cell migration is distinct from the one played by RhoA. They find a correlation between RhoB plasma membrane localization and formation of blebs, and they show that plasma membrane-localized overexpressed RhoB induces blebbing. Further analysis suggests that trafficking of RhoB and specific kinesins may be important for RhoB-mediated blebbing.
The investigation of the specific role of RhoB in blebbing and its link to cell migration/invasion is an interesting aim. The study includes a long series of experiments performed by using distinct experimental settings, which are not always clearly linked conceptually. Moreover, a major concern is the over-interpretation of several data without a substantial experimental support or quantification (see examples in the specific comments below). This concern should be carefully addressed throughout the manuscript. In general, it is this reviewer's opinion that in depth and more complete analysis of fewer aspects among those investigated in the study, would have resulted in a more informative and coherent study of the mechanisms underlying RhoB function in blebbing and motility.
The following specific issues have to be addressed.
Page 6-7: several conclusions are drawn by referring to a few cells shown in Figure 2D -E, and S2D. But these conclusions need to be substantiated by adequate experimental data and quantitative analysis. For example, how defects in retraction were demonstrated is not clear: the authors only show a clear elongation of some of the cells (e.g. panel 2B and movie S2), but no data are provided in support of the link between this type of cell shape and a possible retraction defect. The same criticism applies to the conclusions that "RhoB-siRNA led to a strong decrease in membrane bleblabelling F-actin structures, along with decreased cell area and elongation, as well as increased cell roundness and solidity ( Figures 2D, 2E , S2C and S2D)." And to the following sentence on "retraction-associated actin filaments" (?) and "decreased solidity" (?) . No experiments nor quantitative analysis supporting most of these conclusions are provided. For actin, the graph does not include the evaluation of the significance of the differences observed. pMLC should be defined the first time it is used in the text. In Figure 2C ,E: statistical analysis with adequate tests is missing; significant differences need to be indicated in the graphs. Another example of overinterpretation and inadequate analysis to support a conclusion (Figure 2F-G): immunofluorescence does not exclude a decrease of the total MLC protein after Rho silencing. Immunoblotting to detect the levels of pMLC normalized to total MLC protein in silenced and control cells should be shown to properly look at the effects of Rho silencing on pMLC levels.
Based on the analysis of the localization of endogenous RhoB at the plasma membrane of blebsforming cells, and on the findings that blebbing is induced in H1299 cells overexpressing GFPRhoB, but not Flag-RhoB, the authors conclude that the localization of RhoB at the plasma membrane induces membrane blebbing. The different effects of GFP-RhoB versus Flag-RhoB in these cells is not explained, and raises questions about the specificity of these effects, and about the mechanisms involved. In these experiments, blebbing so far appears to be an artefact by overexpression of GFP-RhoB, while no proof is shown that blebbing is dependent on the localization of RhoB at the plasma membrane per se. Given the differences observed between Flagand GFP-RhoB, the experiments performed with WT and mutant GFP-RhoB (Figure 4 ) do not exclude non-specific, uncontrolled effects due to the GFP-RhoB fusion protein. What happens if untagged RhoB is overexpressed in these cells? Is untagged RhoB able to localize to the plasma membrane of these cells when overexpressed? If so, does the overexpression of an untagged mutant lacking the signature for membrane localization prevent blebbing? These experiments would help clarifying whether the effects observed are due to the recruitment of RhoB at the membrane.
At page 13 ( Figure 6A -B) authors find that incubation at 16{degree sign}C blocks blebbing, proposing that this may be due to block of recycling. Still, a decrease by about 20{degree sign}C with respect to the normal culture conditions may impact a complex process such as blebbing in many different ways, which are not considered in the study: so this conclusion is very weak and should be omitted, unless further proofs are included in support of a specific effect linking recycling with blebbing at reduced temperatures, which by itself would be an interesting issue to be addressed.
In a series of experiments using different experimental systems, the authors address the role of specific kinesins in the regulation of RhoB trafficking, blebbing and migration. This part should be simplified and made more clear: the rationale of each set of experiments, and the links among the different observations obtained by the distinct experimental settings should be better presented. The way it is written, this part is very difficult to read, and the rationale sometimes hard to catch.
Referee #3:
Notes on the manuscript:
In this manuscript, the authors Tachikawa et al. report that the plasma membrane association of the small GTPase RhoB controls membrane blebbing and amoeboid migration in several cancer cell lines. As expected, they show that GTP-binding and geranylation (membrane association) of RhoB is important for its activity. They show that the localisation of RhoB varies between endogenous and tagged RhoB constructs, but that the steady state localisation of RhoB seems to be at LE with a smaller PM pool. The PM localisation of RhoB correlates with its ability to drive membrane blebbing. The authors propose that RhoB is internalised by several distinct pathways into early endosomes, and through maturation into late endosomes and that RhoB can be recycled to the PM via KIF13A. KIF13A is also shown to affect membrane blebbing. This is a very interesting and relevant study in an important scientific area. The manuscript is well written and easy to follow, although some parts of the manuscripts could be shortened. The data are nicely presented in the figures. Yet, there are a number of questions and clarifications to make before the conclusions form the paper match the data presented. In particular, the role of the localisation, endocytic mechanism, trafficking, recycling of RhoB for its influence on membrane blebbing is not clear. Some conclusions are overstatements judging from the data presented and should be removed in order not to distort the main message.
Major points:
1. The authors show that the PM localisation of RhoB correlates with its ability to induce membrane blebbing. However, in the analysis, localisation is compared between endogenous RhoB and FLAGtagged or EGFP/RFP-tagged RhoB and in between different cell lines. This makes it hard to decipher the influence of tags, other molecules, expression levels and cell line specific properties. FLAG-tagged RhoB seem to mimic the endogenous localisation, but EGFP-tagged seem to be somehow impaired in its endocytic turnover. This is why it induces membrane blebbing, but overexpression of the FLAG tagged does not. In order to draw conclusions regarding the role of RhoB trafficking and membrane blebbing this needs to be addressed (See also point 3, 4, 7 below). I would suggest to in a more systematic way use the endogenous RhoB to analyse and describe its localisation and trafficking. Page 8 Line 15: "delete localised at the PM" since the siRNA treatment does not in it self show that it is just PM localised RhoB.
2. The data using mutants of RhoB to show that GTP binding and geranylation is important for its effect on membrane blebbing is nice, but the text could be shortened since it is not so surprising given all the previous literature on small GTPases. The Q63 mutation which blocks GTP hydrolysis has no effect on the ability of RhoB to drive membrane blebbing. Is there a reason not to conclude that GTP hydrolysis is not required? 3. Again when the authors study the localisation of RhoB in relation to markers of internal compartments such as EE LE LY, it is not clear why they sometimes use FLAG tagged, EGFP or endogenous. For this study it is important to clarify the steady state localisation and trafficking routes of RhoB. It seems from the endogenous protein that it is localised mainly to LE, lysosomes (rab7-positive), similarly to FLAG tagged. It is then claimed (Page 11 line 12-14) that RFP tagged mutant (19N) RhoB localises to this compartment, which the authors claim indicates that the GTP binding is affecting the localisation? What is the logic behind this? It needs to be clarified how RhoB is trafficked.
To address trafficking the already present FRAP analysis should be improved and highlighted in the main figures. These data are important to decipher the membrane cytosol and trafficking of RhoB. Furthermore, after clarification of the differences between different constructs, the authors should show live cell trafficking of the maturation of trafficking of RhoB from EE to LE and ERC. This would strongly support the proposed trafficking route of RhoB.
4. The analysis of cell surface removal or internalization does not meet the standard of the field. Numerous studies have reported that drugs cannot be used to address the specificity of endocytic mechanisms but now many marker proteins have been described that can be used to address the mechanism of endocytosis. The authors claim that several distinct pathways are used, but this is not supported by the data and overall the data on endocytosis is very weak. Partial co-localisation with Tfn and CTxB does not tell us anything about the endocytic mechanism. Both Tfn and CTxB are trafficked to EE and in addition CTxB is known to be taken up by several pathways CME, CLIC, caveolae. Preise analysis of the EGFP-RhoB is probably not relevant since the whole cell surface is covered in EGFP RhoB and its internalisation will not be specific. Having said that, I don't think that the endocytic mechanism is key to this story. Showing that it is internalised via endocytosis and that this controls its effect on membrane blebbing would be sufficient without going into details about the endocytic mechanism. As it stands now I would suggest to remove all data and statements about endocytic mechanism and just show that it is removed from the cell surface by endocytosis. By using FRAP of the internal vesicles this could be visualised more clearly. Also use the drug analysis to claim that it is endocytosis without specifying weather or not it is via distinct or separate mechanisms 5. Page 13 line 6: By using incubation at 16 degrees, the authors suggest that recycling might be involved. Many processes at the PM are effected by incubation of cells at 16 degrees endocytosis, membrane properties etc. This section and data are not required and confusing and should be removed.
6. The author's vaguely mention a screen? why kinesins and sorting nexins? Where is the screen described? No reference or no data on how this is performed? How was KIF13A picked out of this screen? How should we evaluate KIF13A in relation to other proteins? 7. Again when studying the effects of KIF13A on RhoB localisation the authors look at FLAG and endogenous RhoB (and later EGFP tagged) and the reader is left but wondering how this relates to previous data and what one should conclude about trafficking. The confusion is further supported by complete speculations page 14 lanes 6-11. As mentioned above, the enrichment of EGFP tagged RhoB to the PM suggests that it is somehow sequestered. Here the authors give some potential explanations to this but there could be many more potential explanations. It could be that the EGFP tag affects the trafficking of RhoB so that it is retained at the PM. Most data points to this option. This is central for the interpretation of many of the conclusions in the paper and should be address early in the study, as suggested above. In Fig 6G the author provide more convincing data looking at the endogenous RhoB.
It is proposed that RhoB is recycled via ERC in a process that requires KIF13A. The authors show that following KIF13A KD there is a small enrichment of RhoB in rab11 positive ERC. Why is this done in H1299 cells and EGFP RhoB? When KIF13A is removed there should be enrichment in the ERC that could be visualised using endogenous RhoB and a marker of ERC? 9. The model should be adjusted. Since the data on several endocytic mechanism are poorly supported this should be removed from the model. Cell surface removal by endocytosis would be sufficient without stating the precise mechanism. Also the ERC needs to be supported if it should remain in the model.
Minor points 1. Page 13 lane 1-2: Degradation? How would this work? By internalisation into multi vesicular bodies. Not shown and the effect on protein levels could be due to many things-remove this statement.
1st Revision -authors' response enter date
Referee #1:
In this manuscript, a role for the RhoB GTPase in plasma membrane blebbing and amoeboid migration has been characterized. The KIF13A kinesin was determined to be essential for proper subcellular localization, and hence function, of RhoB. In addition, endosomal trafficking was also found to be critically important for RhoB localization to plasma membranes, where it signals through ROCK kinases to mediate actin-myosin contraction and blebbing.
The results are robust and convincing, the statistics are generally appropriate. The manuscript is well organized and clearly written, the conclusions are well supported by the data. The controls are generally well designed and provide support for the results.
We appreciate that this reviewer finds our study in general to be interesting and of high quality.
Overall, the manuscript is convincing and interesting. There seems to be one major problematic area, however. The sections on MS page 10-11 on post-translational modifications at the Cterminus. The C192 has been shown to be the site of palmitoylation, while C193 is typically geranylgeranlylated, but which can be farnesylated in some conditions. This section of the manuscript indicates that there can be double prenylation on C192-C193, which I am not aware of. The palmitoylation of C192 has been shown to be essential for RhoB function, so the fact that the C192S mutant was altered in its localization is not entirely surprising. However, this section of the manuscript needs quite a bit of correction.
We thank the Reviewer for pointing this out. It is correct that C192 can only be palmitoylated. However, the C192S mutant also impairs the geranylgeranylation, but not the farnesylation of RhoB on C193 (Adamson, et al. J Biol Chem 1992). We apologize that we did not explain this clearly enough in our initial MS and have now added clarification of this (page 11, lines 10-11). We also agree that the palmitoylation of RhoB appears to regulate its localization (Michaelson et al. J Cell Biol 2001) and have now included the potential effect of C192 palmitoylation in the interpretation of our data (page 11, lines 12-14).
There are a number of instances where treatments have affected RhoB induced blebbing and/or motility that would be more convincing if the same conditions were used to determine whether ROCK induced blebbing was similarly affected. For example, chloroquine or KIF13A knockdown that both affect RhoB induced blebbing would be supported to a significantly greater extent if the same conditions were used with ROCK induced blebbing. These experiments would confirm that the observed effects occur at the level of RhoB, rather than at the level of actin-myosin contraction. On MS page 7 and elsewhere, can the term "cell solidity" be defined?
As suggested, we have added the definition of "cell solidity" (Page 7, lines 8-9).
Figures, such as 3B, that are provided to support the vesicular localization of RhoB would be improved with higher magnification panels that give better visualization of the protein location.
As suggested, we now show vesicular localization of RhoB with high magnification images in Figure  3B .
On MS page 11, is "TagRFP-tagged RhoB" correct? In the figures, it isn't always clear which conditions are being compared to which when the statistical significance is indicated by asterisks. Could this be indicated in the figure, or at least described in the figure legends.
As suggested, all the comparisons are now indicated in a self-explanatory manner in the figures.
Referee #2:
Page 6-7: several conclusions are drawn by referring to a few cells shown in Figure 2D -E, and S2D. But these conclusions need to be substantiated by adequate experimental data and quantitative analysis. For example, how defects in retraction were demonstrated is not clear: the authors only show a clear elongation of some of the cells (e.g. panel 2B and movie S2), but no data are provided in support of the link between this type of cell shape and a possible retraction defect. The same criticism applies to the conclusions that "RhoB-siRNA led to a strong decrease in membrane bleblabelling F-actin structures, along with decreased cell area and elongation, as well as increased cell roundness and solidity ( Figures 2D, 2E , S2C and S2D)." And to the following sentence on "retraction-associated actin filaments" (?) and "decreased solidity" (?) . No experiments nor quantitative analysis supporting most of these conclusions are provided. For actin, the graph does not include the evaluation of the significance of the differences observed. pMLC should be defined the first time it is used in the text. Figure S2C in our original Ms (current Fig EV1O) and exemplified in images of other figures (Fig 2D) .
We apologize that we did not make the performed quantifications sufficiently clear. We have now improved the specifications on the quantifications upon which our conclusions are based. We have also significantly increased the sample size for Figs 2D-E to 105-121 cells/condition from 5 independent experiments. F-actin was visualized in T-ALL cells within 3D-collagen, by imaging 105-121 cells of different conditions in 3D z-stacks in high resolution. The dataset has been quantified and statistical evaluation has been performed (Fig 2E). We also agree that we cannot determine if a fiber necessarily stems from a retraction and have therefore removed the term 'cells with retraction-associated actin filaments'.

We have also improved the specification of how defect cell retraction was concluded. In fact, there is an established use of elongated tails to conclude defect rear retraction in migration, including as a result of RhoA inhibition (Worthylake, et al. J Cell Biol 2001; Vega FM, et al. J Cell Biol 2011). However, our conclusions on defect retraction was not determined from stationary images, but instead inferred from the live cell imaging. As explained in the text (Page 6, lines 20-22), cells shown in Fig 2B and Movies 1-2 are representative examples from live cell imaging of a total of 748 cells. Cells inhibited in their motion by impaired retraction maintain their protrusive dynamics at the migration front end but with no or very slow overall movement, thereby creating an elongated rear tail, just like we observed in some of the cells from our live cell movies (Figs 2B-C; Movies 1-2).
However, we have been somewhat confused about the comment "RhoB-siRNA led to a strong decrease in …. No experiments nor quantitative analysis supporting most of these conclusions are provided'. These conclusions were based on the quantitative analysis shown in
As suggested, we have added the definition of pMLC the first time it is used in the text (Page 7, line 19).
In Figure 2C ,E: statistical analysis with adequate tests is missing; significant differences need to be indicated in the graphs.
As suggested, we now include statistical analysis in these graphs based on Dunnett's multiple comparison test.
Another example of overinterpretation and inadequate analysis to support a conclusion ( Figure 2F -G): immunofluorescence does not exclude a decrease of the total MLC protein after Rho silencing.
Immunoblotting to detect the levels of pMLC normalized to total MLC protein in silenced and control cells should be shown to properly look at the effects of Rho silencing on pMLC levels.
As suggested, we have now added immunoblotting to detect the levels of pMLC and total MLC protein after perturbation (Fig EV1R).
Based on the analysis of the localization of endogenous RhoB at the plasma membrane of blebsforming cells, and on the findings that blebbing is induced in H1299 cells overexpressing GFPRhoB, but not Flag-RhoB, the authors conclude that the localization of RhoB at the plasma membrane induces membrane blebbing. The different effects of GFP-RhoB versus Flag-RhoB in these cells is not explained, and raises questions about the specificity of these effects, and about the mechanisms involved. In these experiments, blebbing so far appears to be an artefact by overexpression of GFP-RhoB, while no proof is shown that blebbing is dependent on the localization of RhoB at the plasma membrane per se. Given the differences observed between Flagand GFP-RhoB, the experiments performed with WT and mutant GFP-RhoB ( Figure 4 ) do not exclude non-specific, uncontrolled effects due to the GFP-RhoB fusion protein. What happens if untagged RhoB is overexpressed in these cells? Is untagged RhoB able to localize to the plasma membrane of these cells when overexpressed? If so, does the overexpression of an untagged mutant lacking the signature for membrane localization prevent blebbing? These experiments would help clarifying whether the effects observed are due to the recruitment of RhoB at the membrane.
We understand the concern on the EGFP-RhoB localization. As mentioned in our Ms, 'Both endogenous and EGFP-tagged RhoB reside in two pools; an LE/LY pool and a PM pool. Importantly, the RhoB relative distribution between the PM and vesicles can be tuned by specific perturbations (Garcia-Mariscal et al., 2017; Michaelson et al., 2001; Wherlock et al., 2004), suggesting that a dynamic balance between these two pools is determined by factors such as prenylation state, trafficking, sorting and recycling machineries.' We have used a cell line, H1299, with no endogenous blebbing to investigate possible gain-of-function by RhoB overexpression. However, overexpressed FLAG-RhoB in these cells localizes mainly in vesicles and does not induce blebbing (Fig 3B). FLAG-tagged RhoB thus mimics the localization of endogenous RhoB, and we do not know of any specific way to switch untagged/endogenous RhoB to the PM. Therefore, we have used variants of RhoB whose localization is shifted towards the PM to examine if RhoB localization at the PM is related to blebbing. To this end, we have now added experiments utilizing a mutant of FLAG-tagged RhoB (FLAG-RhoB NFNQ, in which the DYDR motif in the Switch2 domain of RhoB is replaced by NFNQ). This mutation caused a RhoB localization shift to mainly appear at the PM. Importantly, overexpression of FLAG-RhoB NFNQ also induced membrane blebbing (Figs 3C and EV2D). This suggests a role of the DYDR motif in determining RhoB localization and more importantly that a shift of RhoB to PM localization causes membrane blebbing. As a control, we deleted the CAAX box in FLAG-RhoB NFNQ to specifically deprive this mutant of its PM localization. Consequently, this control mutant showed a diffusive cytoplasmic localization and lost the ability to induce blebbing (Figs 3C and EV2D). These results indicate that the effect of RhoB on blebbing is due to its membrane localization.
In addition, adding an N-terminal EGFP tag onto RhoB causes the same shift of localization to the PM as the NFNQ mutant and the resulting induction of blebbing adds further evidence on the correlation between RhoB localization and membrane blebbing. This correlation may not come as a surprise, since it is well established that local Myosin II activity at the PM is critical for blebbing and it appears logical that the regulatory signaling is localized in close proximity.
We agree and have removed this experiment.
We apologize that this was not made sufficiently clear. We have now re-structured this part (Pages 13-14) to obtain a better logical flow and tried to better explain the rationale for each experiment.
Referee #3:
We appreciate that this reviewer finds our study interesting and well presented.
1. The authors show that the PM localisation of RhoB correlates with its ability to induce membrane blebbing. However, in the analysis, localisation is compared between endogenous RhoB and FLAGtagged or EGFP/RFP-tagged RhoB and in between different cell lines. This makes it hard to decipher the influence of tags, other molecules, expression levels and cell line specific properties. FLAG-tagged RhoB seem to mimic the endogenous localisation, but EGFP-tagged seem to be somehow impaired in its endocytic turnover. This is why it induces membrane blebbing, but overexpression of the FLAG tagged does not. In order to draw conclusions regarding the role of RhoB trafficking and membrane blebbing this needs to be addressed (See also point 3, 4, 7 below). I would suggest to in a more systematic way use the endogenous RhoB to analyse and describe its localisation and trafficking. Figs 3A-B and EV2A-C) ;
2) The localization of FLAG-tagged RhoB (Fig 3B); 3) The localization of FLAG-tagged RhoB mutants and their ability to induce blebbing (Figs 3C and  EV2D ; Fig 4A) Figs  EV4A-B) ; 5) The co-localization of FLAG-RhoB with LAMP1 ( Fig 5B); 6) The effect of Rab7 KD on the co-localization of endogenous RhoB with EEA1 or LAMP1 ( Fig  5D) ; 7) The effect of KIF13A KD on the co-localization of endogenous RhoB with Rab11 ( Fig 6C) ; 8) The effect of KIF13A KD on the PM localization of endogenous RhoB in H1299 cells (Fig 6D) and in T-ALL cells (Fig 6F) .
We have also added experiments using a RhoB mutation switching RhoB localization to the PMand consequently induced membrane blebbing (Figs 3C and EV2D).
We now only display use of EGFP-RhoB for live cell imaging, for some gain-of-function experiments as complements to the findings with endogenous and FLAG-tagged RhoB and mutants thereof, and to detect the role of RhoB GTPase activity and prenylation.
Page 8 Line 15: "delete localised at the PM" since the siRNA treatment does not in it self show that it is just PM localised RhoB.
We agree and have corrected the text accordingly.
2. The data using mutants of RhoB to show that GTP binding and geranylation is important for its effect on membrane blebbing is nice, but the text could be shortened since it is not so surprising given all the previous literature on small GTPases. The Q63 mutation which blocks GTP hydrolysis has no effect on the ability of RhoB to drive membrane blebbing. Is there a reason not to conclude that GTP hydrolysis is not required? (Figs 5H-I ).
We agree that the effect of prenylation on the localization of small GTPases in general has
Furthermore, after clarification of the differences between different constructs, the authors should show live cell trafficking of the maturation of trafficking of RhoB from EE to LE and ERC. This would strongly support the proposed trafficking route of RhoB.
As suggested, we have added live cell imaging experiments to track EGFP-RhoB from EE to LE, as well as from EE to recycling endosomes. EGFP-RhoB stable cells were co-transfected with TagRFP-Rab5 and CFP-Rab7 or CFP-Rab11. Live cell imaging was performed showing the trafficking of EGFP-RhoB from Rab5-positive vesicles to Rab7 vesicles (LE marker; Fig 5E and Movie EV6) as well as from Rab5-positive vesicles to Rab11 vesicles (ERC marker; Fig 6B and Movie EV10).
4. The analysis of cell surface removal or internalization does not meet the standard of the field. Numerous studies have reported that drugs cannot be used to address the specificity of endocytic mechanisms but now many marker proteins have been described that can be used to address the mechanism of endocytosis. The authors claim that several distinct pathways are used, but this is not supported by the data and overall the data on endocytosis is very weak. Partial co-localisation with Tfn and CTxB does not tell us anything about the endocytic mechanism. Both Tfn and CTxB are trafficked to EE and in addition CTxB is known to be taken up by several pathways CME, CLIC, caveolae. Preise analysis of the EGFP-RhoB is probably not relevant since the whole cell surface is covered in EGFP RhoB and its internalisation will not be specific. Having said that, I don't think that the endocytic mechanism is key to this story. Showing that it is internalised via endocytosis and that this controls its effect on membrane blebbing would be sufficient without going into details about the endocytic mechanism. As it stands now I would suggest to remove all data and statements about endocytic mechanism and just show that it is removed from the cell surface by endocytosis. By using FRAP of the internal vesicles this could be visualised more clearly. Also use the drug analysis to claim that it is endocytosis without specifying weather or not it is via distinct or separate mechanisms 7. Again when studying the effects of KIF13A on RhoB localisation the authors look at FLAG and endogenous RhoB (and later EGFP tagged) and the reader is left but wondering how this relates to previous data and what one should conclude about trafficking. The confusion is further supported by complete speculations page 14 lanes 6-11. As mentioned above, the enrichment of EGFP tagged RhoB to the PM suggests that it is somehow sequestered. Here the authors give some potential explanations to this but there could be many more potential explanations. It could be that the EGFP tag affects the trafficking of RhoB so that it is retained at the PM. Most data points to this option. This is central for the interpretation of many of the conclusions in the paper and should be address early in the study, as suggested above. In Fig 6G the author provide more convincing data looking at the endogenous RhoB. We agree and have removed this statement.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND #
No specific statistical test was used to predetermine the sample size. All experiments were repeated at least three times, unless stated otherwise in the figure legends.
N/A
Exclusion criteria were applied uniformly among whole experiments and were pre--established. Apparently dead cells in 3D collagen I gel (judged by live cell imaging) after electroporation were excluded for quantification.
Cells were seeded and chosen randomly for transfection or drug treatment. We also prepared medium master mixes for all samples (if applicable) to avoid subjective or biased pippetting volumes of concentrated drugs.
Where possible, samples were analysed blindly. Automated image analysis software Cellprofiler and Imaris were utilized and the same settings were applied for all samples within one experiment.
N/A
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
Please fill out these boxes # (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C--Reagents
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.). This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
